Esperion is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for the treatment of patients with elevated levels of low-density lipoprotein cholesterol (LDL-C) and other cardiometabolic risk factors.
Esperion leadership has exceptional track record in pharmaceuticals
Our founder, executive chairman and chief scientific officer, Roger Newton, PhD, FAHA., co-discovered the statin marketed as Lipitor® (atorvastatin calcium), the most prescribed LDL-C lowering therapy in the world and the best-selling drug in the history of the pharmaceutical industry.
We believe our management team has demonstrated expertise in understanding cholesterol biosynthesis and other related cardiometabolic pathways, the strengths and weaknesses of currently marketed therapies and the ability to recognize the potential of novel cholesterol regulating therapies.
Developing innovative therapies to improve lives
Esperion brings professionalism and integrity to exploring, creating, and building upon our collective understanding of basic science to develop novel therapies for treating cardiovascular and metabolic diseases. We have the courage and expertise to challenge conventional thinking and move innovative science to the forefront of medicine. Esperion seeks to understand the basic science, find its therapeutic applications to treat human disease, and make a difference in patients’ lives.